Top 3 observations of the first-in-human study with novel PCSK9 base editing medicine3' education - Nov. 16, 2023 - Andrew Bellinger, MD, PhD - Boston, MA, US
This video was recorded during the AHA Scientific Sessions 2023 in Philadelphia, PA, US.
Andrew Bellinger, MD, PhD is chief scientific officer of Verve Therapeutics and a general cardiologist at Brigham and Women’s Hospital.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.